Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1979 Nov;16(5):615–621. doi: 10.1128/aac.16.5.615

Clinical Pharmacokinetics and Safety of High Doses of Ceforanide (BL-S786R) and Cefazolin

Robert D Smyth 1, Morris Pfeffer 1, Aaron Glick Donald 1, R Van Harken 1, Girard H Hottendorf 1
PMCID: PMC352915  PMID: 526003

Abstract

The pharmacokinetics and safety of ceforanide and cefazolin were compared in normal subjects after 30-min intravenous infusions of 2-, 3-, and 4-g single doses and 4-g twice-daily doses for 10 days. No significant differences were observed in plasma-renal pharmacokinetic parameters between single and multiple doses of ceforanide. Half-life (t½, 2.8 h), plasma clearance (Clp, 48 ml/min per 1.73 m2), and renal clearance (Cl0−12hr, 47 ml/min per 1.73 m2; tubular secretion, 44%, and glomerular filtration, 56%) did not change with increased dose or on multiple dosing. No significant change was observed in t½ (1.9 h), area under the plasma concentration-time curve, Clr (60 ml/min per 1.73 m2; tubular secretion, 80%, and glomerular filtration, 20%), or Clp (75 ml/min per 1.73 m2) for 4-g single doses compared with twice-daily administration of cefazolin. A small increase in cefazolin clearance was observed when plasma concentrations were greater than 100 μg/ml, when the single dose was increased from 2 to 4 g; this was a result of the decrease in percentage of plasma protein binding and increased renal clearance due to increased glomerular filtration. The increase in renal clearance resulted in a lack of linear proportionality of the plasma area under the curve with dose over a range of 2 to 4 for both cephalosporins, although this effect was much less marked with ceforanide. Both compounds were well tolerated both locally and systemically. There was no evidence of any change in renal function based on clearances of drug, p-aminohippuric acid, or creatinine, and other standard clinical parameters.

Full text

PDF
615

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andriole V. T. Pharmacokinetics of cephalosporins in patients with normal or reduced renal function. J Infect Dis. 1978 May;137 (Suppl):S88–S99. doi: 10.1093/infdis/137.supplement.s88. [DOI] [PubMed] [Google Scholar]
  2. Barza M. The nephrotoxicity of cephalosporins: an overview. J Infect Dis. 1978 May;137 (Suppl):S60–S73. doi: 10.1093/infdis/137.supplement.s60. [DOI] [PubMed] [Google Scholar]
  3. Baum N., Dichoso C. C., Carlton C. E. Blood urea nitrogen and serum creatinine. Physiology and interpretations. Urology. 1975 May;5(5):583–588. doi: 10.1016/0090-4295(75)90105-3. [DOI] [PubMed] [Google Scholar]
  4. Birkhead H. A., Briggs G. B., Saunders L. Z. Toxicology of cefazolin in animals. J Infect Dis. 1973 Oct;128(Suppl):S379–S378. doi: 10.1093/infdis/128.supplement_2.s379. [DOI] [PubMed] [Google Scholar]
  5. Brodwall E. K., Bergan T., Orjavik O. Kidney transport of cefazolin in normal and impaired renal function. J Antimicrob Chemother. 1977 Nov;3(6):585–592. doi: 10.1093/jac/3.6.585. [DOI] [PubMed] [Google Scholar]
  6. DOOLAN P. D., ALPEN E. L., THEIL G. B. A clinical appraisal of the plasma concentration and endogenous clearance of creatinine. Am J Med. 1962 Jan;32:65–79. doi: 10.1016/0002-9343(62)90183-3. [DOI] [PubMed] [Google Scholar]
  7. Jones R. N., Thornsberry C., Barry A. L., Fuchs P. C., Gavin T. L., Gerlach E. H. BL-S786, a new parenteral cephalosporin. II. In vitro antimicrobial activity comparison with six related cephalosporins. J Antibiot (Tokyo) 1977 Jul;30(7):583–592. doi: 10.7164/antibiotics.30.583. [DOI] [PubMed] [Google Scholar]
  8. Leitner F., Misiek M., Pursiano T. A., Buck R. E., Chisholm D. R., DeRegis R. G., Tsai Y. H., Price K. E. Laboratory evaluation of BL-S786, a cephalosporin with broad-spectrum antibacterial activity. Antimicrob Agents Chemother. 1976 Sep;10(3):426–435. doi: 10.1128/aac.10.3.426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Loo J. C., Riegelman S. Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion. J Pharm Sci. 1970 Jan;59(1):53–55. doi: 10.1002/jps.2600590107. [DOI] [PubMed] [Google Scholar]
  10. Nightingale C. H., Greene D. S., Quintiliani R. Pharmacokinetics and clinical use of cephalosporin antibiotics. J Pharm Sci. 1975 Dec;64(12):1899–1926. doi: 10.1002/jps.2600641202. [DOI] [PubMed] [Google Scholar]
  11. Singhvi S. M., Heald A. F., Gadebusch H. H., Resnick M. E., Difazio L. T., Leitz M. A. Human serum protein binding of cephalosporin antibiotics in vitro. J Lab Clin Med. 1977 Feb;89(2):414–420. [PubMed] [Google Scholar]
  12. Slack T. K., Wilson D. M. Normal renal function: CIN and CPAH in healthy donors before and after nephrectomy. Mayo Clin Proc. 1976 May;51(5):296–300. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES